First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Introduction. In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hyp...

Full description

Bibliographic Details
Main Authors: Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Format: Article
Language:English
Published: Endocrinology Research Centre 2015-01-01
Series:Сахарный диабет
Subjects:
diabetes mellitus type 2
glycated hemoglobin
нbа1с
dpp-4 inhibitor
gosogliptin
vildagliptin
Online Access:https://dia-endojournals.ru/dia/article/viewFile/7233/5609

Similar Items

Similar Items